Why does Market Access pay so well in Germany?
Because Germany's AMNOG process, with the early-benefit assessment by the G-BA and IQWiG, largely determines a medicine's price and reimbursement. Companies live or die commercially by how well they navigate it, so genuine AMNOG expertise is highly valued and hard to replace. That scarcity is what supports the premium. It also means employers reward people who understand the German system specifically, not generic access experience.
Market Access is one of the most strategically important functions in pharma, and in the DACH region it is unusually specialised because of one thing: AMNOG. If you are a health economist, an evidence specialist or a commercially-minded scientist wondering where the well-paid, defensible careers are, this is a corner of pharma worth understanding.
Having recruited commercial and scientific talent inside pharma, here is why the specialism commands what it does, and how to position for it.
What Market Access actually does
Market Access secures a price and reimbursement for a medicine and defends its value to payers. The work spans pricing and reimbursement strategy, health-technology assessment submissions, value dossiers, health-economic and outcomes research (HEOR), real-world evidence and payer engagement. It sits at the commercial-scientific intersection, and it increasingly decides whether a launch succeeds at all.
Why AMNOG changes everything in Germany
Germany runs one of the most consequential value-assessment systems in Europe. Under AMNOG, new medicines undergo an early-benefit assessment by the G-BA, informed by IQWiG, that heavily shapes the price a company can command. The quality of the value dossier and the strategy behind it have real commercial consequences, so companies invest in people who can do this well. Because AMNOG expertise is specific, evidence-heavy and hard to fake, the people who hold it are scarce, and scarcity is what supports the premium. Switzerland and Austria add their own demanding processes on top.
What a Market Access CV has to show
Strong Market Access CVs are specific about submissions and outcomes. They name the systems worked in, the dossiers delivered, the therapeutic areas and the payer results. Concretely: pricing and reimbursement, health-technology assessment, AMNOG and G-BA/IQWiG dossiers, value and evidence generation, health-economic modelling, real-world evidence and payer engagement. For HEOR specifically, modelling, systematic review and outcomes research come to the front. A CV that only says "responsible for market access" gives a recruiter nothing to rank.
For the full picture of the function, the employers hiring across DACH, and the in-house-versus-consultancy split, see the dedicated guide: Market Access & HEOR careers in DACH pharma.
How to break in, and move up
People arrive in Market Access from health economics, epidemiology, clinical and commercial backgrounds. The move from an adjacent function works when your evidence, commercial or clinical experience is translated into access and value language, and when you can show, or credibly build toward, national-system knowledge. AMNOG understanding is the differentiator: how you present your German HTA experience matters a great deal, and German is frequently important given the payer landscape.
A note on salary
Market Access is well paid, but I will not quote a band, because the range depends on level, in-house versus consultancy, therapeutic area and how much genuine AMNOG and HEOR depth you carry. A number stripped of those variables would mislead. The honest point is that the specialism itself, and demonstrable national-system expertise, moves the range more than any negotiation.
The move that actually works
Whether you are breaking in or moving up, it rarely happens by applying cold. It works when your evidence and access experience is translated into the language recruiters search for, your CV passes the ATS, and you are put in front of the companies and consultancies that hire in this space, including the roles that never reach the job boards.
© 13 July 2026 Andreas Schulz. All rights reserved.
Targeting a Market Access or HEOR move?
Book a free getting-to-know call. I will tell you honestly how your evidence and access experience reads to hiring managers, and how to position it for the DACH market.
Book a Free Getting to Know Call